Factors That Govern the Induction of Long-Lived Antibody Responses

Chackerian, Bryce; Peabody, David S.

doi:10.3390/v12010074

Cited by 27 publications

(24 citation statements)

References 65 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the span of a nearly two-year period following vaccination, mouse anti-CSP antibody titers did not decline. These data add to a growing body of literature demonstrating that the ability to induce long-lived plasma cells is a feature of vaccine antigens, such as VLPs, with highly multivalent structures [27][28][29] . Our study provides evidence that use of a multivalent vaccine technology can effectively elicit durable antibody responses against CSP.…”

Section: Cis43 Vlps Elicit Anti-csp Antibody Responses In Non-human Psupporting

confidence: 52%

“…We and others have previously shown that vaccination with VLPs can elicit differentiation of long-lived plasma cells (LLPCs), resulting in stable, long-lasting antibody levels [27][28][29] . It is likely that long-lived circulating antibodies will be required for sustained protection from malaria infection in endemic areas, where reinfection is common.…”

Section: Cis43 Vlps Induce High Titer Antibody Responses Against Cspmentioning

confidence: 99%

“…As a strategy to increase antibody titers elicited by CIS43 VLPs, we tested the compatibility of CIS43 VLPs with Advax adjuvants. Advax adjuvants contain delta inulin polysaccharides that have been shown to enhance both the cellular and humoral immune responses to a variety of antigens and can be combined with other immunostimulatory agents, such as CpG oligonucleotides 28,29 . Mice were immunized three times with CIS43 VLPs in combination with five different Advax formulations (Advax 1-5), CpG oligonucleotides alone, or without exogenous adjuvant, and then antibody levels were determined by ELISA.…”

Section: Immunization With Cis43 Vlps Protects Mice From Intravenous mentioning

confidence: 99%

See 2 more Smart Citations

An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein

Jelínková

Jhun

Eaton

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

A malaria vaccine that elicits long-lasting protection and is suitable for use in endemic areas remains urgently needed. Here, we assessed the immunogenicity and prophylactic efficacy of a vaccine targeting a recently described epitope on the major surface antigen on Plasmodium falciparum sporozoites, circumsporozoite protein (CSP). Using a virus-like particle (VLP)-based vaccine platform technology, we developed a vaccine that targets the junctional region between the N-terminal and central repeat domains of CSP. This region is recognized by monoclonal antibodies, including mAb CIS43, that have been shown to potently prevent liver invasion in animal models. We show that CIS43 VLPs elicit high titer and long-lived anti-CSP antibody responses in mice and non-human primates. Immunization with CIS43 VLPs confers partial protection from malaria infection in a mouse model, and both immunogenicity and protection were enhanced when mice were immunized with CIS43 VLPs in combination with adjuvants including delta inulin polysaccharide particles and TLR9 agonists. Passive transfer of serum from immunized macaques also inhibited parasite liver invasion in the mouse infection model. Our findings demonstrate that a Qβ VLP-based vaccine targeting the CIS43 epitope combined with various adjuvants is highly immunogenic in mice and macaques, elicits long-lasting anti-CSP antibodies, and inhibits parasite infection in a mouse model. Thus, the CIS43 VLP vaccine is a promising pre-erythrocytic malaria vaccine candidate.

show abstract

Section: Cis43 Vlps Elicit Anti-csp Antibody Responses In Non-human Psupporting

confidence: 52%

Section: Cis43 Vlps Induce High Titer Antibody Responses Against Cspmentioning

confidence: 99%

Section: Immunization With Cis43 Vlps Protects Mice From Intravenous mentioning

confidence: 99%

See 1 more Smart Citation

An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein

Jelínková

Jhun

Eaton

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some experimental vaccine platforms tolerate the incorporation of large antigens and even full-sized proteins in viral structures without influencing the particle morphology and immune-stimulating properties. As the native spatial structures of recombinant antigens are highly important for eliciting antibodies with neutralizing activity and long-lasting immunity [97,98], future recombinant VLP vaccines must contain multiple copies of correctly folded antigens as well as different immunostimulating components, including T-cell epitopes and nucleic acids.…”

Section: Discussionmentioning

confidence: 99%

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

Baļķe

Zeltiņš

2020

Viruses

View full text Add to dashboard Cite

Vaccination is one of the most effective public health interventions of the 20th century. All vaccines can be classified into different types, such as vaccines against infectious diseases, anticancer vaccines and vaccines against autoimmune diseases. In recent decades, recombinant technologies have enabled the design of experimental vaccines against a wide range of diseases using plant viruses and virus-like particles as central elements to stimulate protective and long-lasting immune responses. The analysis of recent publications shows that at least 97 experimental vaccines have been constructed based on plant viruses, including 71 vaccines against infectious agents, 16 anticancer vaccines and 10 therapeutic vaccines against autoimmune disorders. Several plant viruses have already been used for the development of vaccine platforms and have been tested in human and veterinary studies, suggesting that plant virus-based vaccines will be introduced into clinical and veterinary practice in the near future.

show abstract

“…This is due to the importance of preventing the initial infection of these pathogens. In such cases, memory B-cell dependent humoral responses would not be sufficient [121]. While the HBV vaccine has shown to be effective and has decreased HBV prevalence worldwide [122], the long-term efficacy of the HBV vaccine is memory B-cell dependent.…”

Section: Effect Of Platform Rigiditymentioning

confidence: 99%

Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines

Aves

Goksøyr

Sander

2020

Viruses

View full text Add to dashboard Cite

Capsid-like particles (CLPs) are multimeric, repetitive assemblies of recombinant viral capsid proteins, which are highly immunogenic due to their structural similarity to wild-type viruses. CLPs can be used as molecular scaffolds to enable the presentation of soluble vaccine antigens in a similar structural format, which can significantly increase the immunogenicity of the antigen. CLP-based antigen display can be obtained by various genetic and modular conjugation methods. However, these vary in their versatility as well as efficiency in achieving an immunogenic antigen display. Here, we make a comparative review of the major CLP-based antigen display technologies. The Tag/Catcher-AP205 platform is highlighted as a particularly versatile and efficient technology that offers new qualitative and practical advantages in designing modular CLP vaccines. Finally, we discuss how split-protein Tag/Catcher conjugation systems can help to further propagate and enhance modular CLP vaccine designs.

show abstract

Factors That Govern the Induction of Long-Lived Antibody Responses

Cited by 27 publications

References 65 publications

An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein

An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein

Recent Advances in the Use of Plant Virus-Like Particles as Vaccines

Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines

Contact Info

Product

Resources

About